Skip to main
EW

Edwards Lifesciences (EW) Stock Forecast & Price Target

Edwards Lifesciences (EW) Analyst Ratings

Based on 18 analyst ratings
Buy
Strong Buy 39%
Buy 44%
Hold 17%
Sell 0%
Strong Sell 0%

Bulls say

Edwards Lifesciences is a leader in the medical device industry and is expected to continue its strong growth due to its innovative products and upcoming market-expanding catalysts. The company has a solid financial profile, with strong revenue both domestically and internationally, and a diverse portfolio of products that target various stages of structural heart disease. Risks include regulatory and competitive challenges, but the company's strong financials and upcoming catalysts make it an attractive investment opportunity.

Bears say

Edwards Lifesciences is currently facing margin headwinds from tariffs and its premium valuation may not be sustainable in the long term given the emergence of alternative treatments in the cardiovascular market. Additionally, while its TAVR business may have stabilized, growth potential may be limited in the future. Competitors such as Abbott Laboratories and Medtronic have higher price targets and may present better long-term opportunities for investors.

Edwards Lifesciences (EW) has been analyzed by 18 analysts, with a consensus rating of Buy. 39% of analysts recommend a Strong Buy, 44% recommend Buy, 17% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Edwards Lifesciences and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Edwards Lifesciences (EW) Forecast

Analysts have given Edwards Lifesciences (EW) a Buy based on their latest research and market trends.

According to 18 analysts, Edwards Lifesciences (EW) has a Buy consensus rating as of Sep 16, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $102, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $102, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Edwards Lifesciences (EW)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.